Treatment News : HIV/Hep B Coinfection Responds Very Well to Viread

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 9, 2013

HIV/Hep B Coinfection Responds Very Well to Viread

The HIV antiretroviral Viread (tenofovir) is highly effective in combating both HIV and hepatitis B virus (HBV) among those coinfected with both viruses, aidsmap reports. Publishing their findings in PLOS ONE, researchers from the University College London performed a meta-analysis of 23 studies, most of them observational, that examined the treatment outcomes of HIV/HBV coinfected people receiving Viread. The follow-up period spanned as long as seven years, however the researchers narrowed their analysis to three years to ensure greater statistical weight to their conclusions.

Fifty-seven percent of the study participants achieved fully suppressed hep B after one year of treatment. This figure increased to 79 percent at two years and 86 percent at the three-year mark. Virological rebound occurred in just 2.4 percent of cases.

There was no apparent benefit in adding Epivir (lamivudine) or Emtriva (emtricitabine) to Viread.

The analysis was limited by the fact that it mostly looked at observational studies, which carry less significant scientific conclusions, in part because they are not designed by a process of randomization. Also, there was insufficient data on the participants who dropped out of the studies, and the analysis did not examine side effects. Generally safe and well tolerated, Viread can lead to bone loss and kidney problems in those who are at risk for such health problems.

To read the aidsmap story, click here.

To read the study, click here.

Search: HIV, antiretroviral, Viread, tenofovir, HBV, hepatitis B virus, hep B, PLOS ONE, coinfection, virological rebound, full suppression, Epivir, lamivudine, Emtriva, emtricitabine.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    adorableone
    New York
    New York


    Sloan1
    Dallas
    Texas


    hollywoodvers1
    Los Angeles
    California


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.